An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
- 9 April 2014
- journal article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 73 (6), 1227-1239
- https://doi.org/10.1007/s00280-014-2459-z
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trialThe Lancet Oncology, 2011
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerThe New England Journal of Medicine, 2008
- Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinomaCancer Science, 2008
- The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibilityProceedings of the National Academy of Sciences of the United States of America, 2008
- EGFR, HER2, and HER3 Expression in Laryngeal Primary Tumors and Corresponding MetastasesAnnals of Surgical Oncology, 2008
- Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neckRadiotherapy and Oncology, 2007
- Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based TherapyJournal of Clinical Oncology, 2007
- A Retrospective Analysis of the Outcome of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Refractory to a Platinum-based ChemotherapyClinical Oncology, 2005
- Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer TherapyThe Journal of Immunology, 2004
- Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient SurvivalJNCI Journal of the National Cancer Institute, 1998